甲型H1N1流感单价疫苗在肾移植受者和透析患者中的有效性和安全性。
Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients.
作者信息
Beaudreuil Séverine, Krivine Anne, Hebibi Hadia, Ducot Béatrice, Mazet Anne-Aurélie, Taouffik Yacine, Seidowsky Alexandre, Jacquet Antoine, Lorenzo Hans Kristian, Charpentier Bernard, Francois Hélène, Durrbach Antoine
机构信息
Nephrology IFRNT, University Hospital, Le Kremlin Bicetre, France.
出版信息
Hum Vaccin. 2011 Aug;7(8):868-73. doi: 10.4161/hv.7.8.16083. Epub 2011 Aug 1.
BACKGROUND
The (H1N)1v influenza virus infection emerged in 2009 as a serious disease in targeted populations. Herein, we report on the tolerability and efficacy of (anti-H1N1)v vaccination in dialysis and transplant patients.
METHODS
18 renal-transplant recipients (RTR) and 19 dialysis patients (DP) [12 patients treated with peritoneal dialysis (PDP), 7 patients treated with haemodialysis (HDP)] were enrolled. DPs received one monovalent H1N1 adjuvanted-vaccine injection, and RTRs received two unadjuvanted vaccine injections within a 21-day period. Serologic response was defined as a haemagglutination inhibition titre of > 40 (seroprotection) and/or at least a four-fold increase in antibody titre from baseline (seroconversion).
RESULTS
Seroprotection rate after vaccination was greater in DPs than RTRs (p = 0.007), as was seroconversion (p = 0.001). Serologic response was similar in PDPs and HDPs.
CONCLUSIONS
Serologic response was satisfactory in DPs, whichever dialysis mode (DPD or HDP). It was low in RTRs as compared to DPs.
背景
2009年出现的甲型H1N1流感病毒感染在特定人群中是一种严重疾病。在此，我们报告甲型H1N1流感疫苗在透析和移植患者中的耐受性和疗效。
方法
纳入18例肾移植受者（RTR）和19例透析患者（DP）[12例接受腹膜透析（PDP）治疗，7例接受血液透析（HDP）治疗]。透析患者接受一剂单价甲型H1N1佐剂疫苗注射，肾移植受者在21天内接受两剂非佐剂疫苗注射。血清学反应定义为血凝抑制滴度>40（血清保护）和/或抗体滴度较基线至少增加四倍（血清转化）。
结果
透析患者接种疫苗后的血清保护率高于肾移植受者（p = 0.007），血清转化率也是如此（p = 0.001）。腹膜透析患者和血液透析患者的血清学反应相似。
结论
无论采用何种透析方式（腹膜透析或血液透析），透析患者的血清学反应都令人满意。与透析患者相比，肾移植受者的血清学反应较低。
Zotero 插件